STOCK TITAN

Co-Diagnostics, Inc. - CODX STOCK NEWS

Welcome to our dedicated page for Co-Diagnostics news (Ticker: CODX), a resource for investors and traders seeking the latest updates and insights on Co-Diagnostics stock.

Co-Diagnostics, Inc. (NASDAQ: CODX) is a pioneering molecular diagnostics company based in Sandy, Utah. The company is renowned for its unique, patented technology that significantly enhances the speed, performance, and cost-efficiency of DNA testing for a variety of diseases compared to traditional methods. Co-Diagnostics focuses on the development, manufacturing, and commercialization of its proprietary technologies through sales, development, and licensing agreements.

Co-Diagnostics’ core technology is protected by multiple patents and trade secrets, enabling revolutionary approaches in molecular diagnostics. These innovations have been utilized to develop a range of assays in the infectious disease sector, demonstrating the technology's exceptional capabilities. The company's patented inventions stem from advanced mathematical models designed by Dr. Brent C. Satterfield.

The firm’s product portfolio includes diagnostic tests for diseases such as tuberculosis, Zika, hepatitis B and C, malaria, dengue, and HIV. These tests utilize the detection and analysis of nucleic acid molecules (DNA or RNA) to provide accurate and efficient diagnostics. Co-Diagnostics also leverages its proprietary technology to create tests for its Co-Dx PCR platform, which includes at-home and point-of-care solutions.

One of the notable collaborations of Co-Diagnostics is its joint venture with CoSara Diagnostics Pvt Ltd in India. This partnership has led to regulatory clearance from India’s Central Drugs Standard Control Organization (CDSCO) for multiple diagnostic tests, including the SARAPLEX™ Influenza Multiplex (IFM) Test Kit, which differentiates between Influenza A and B strains.

Recently, Co-Diagnostics announced significant milestones, such as the opening of new manufacturing facilities in Salt Lake City, Utah, and Ranoli, India. These facilities will enhance the production of the company’s novel Co-Dx PCR Pro™ instrument and test cups, as well as the Co-Primers™ chemistry that is vital for its PCR diagnostic tests. The Salt Lake City facility, inaugurated with support from local dignitaries and business leaders, marks a critical step in expanding the company's production capabilities.

The company’s forward-looking strategies include submitting an Emergency Use Authorization (EUA) to the FDA for the Co-Dx PCR Pro™ instrument, mobile app, and COVID-19 test. This submission is part of Co-Diagnostics’ effort to decentralize PCR diagnostics and extend its reach to at-home and point-of-care settings. The company is also developing tests for tuberculosis, multiplex respiratory infections, and HPV, among others.

Co-Diagnostics’ financial performance and strategic initiatives are regularly discussed through conference calls and webcasts, involving key executives such as CEO Dwight Egan and CFO Brian Brown. The company remains committed to innovation and growth, aiming to provide accessible and high-quality diagnostic solutions worldwide.

Rhea-AI Summary

Co-Diagnostics, Inc. (Nasdaq-CM: CODX) will present at the 5th Advances in Circulating Tumor Cells (ACTC) conference in Kalamata, Greece, from September 22-25, 2021. The presentation is scheduled for September 23 at 14:50 local time. The Company's Logix Smart™ COVID-19 Tests will be used for on-site testing of attendees, highlighting its expanding presence in Europe. Co-Diagnostics aims to engage with both new and existing customers to showcase its diagnostic products. Interested European distributors and laboratories can contact the Company for more information.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.15%
Tags
conferences
-
Rhea-AI Summary

Co-Diagnostics, Inc. (Nasdaq: CODX) announced that its Logix Smart™ Influenza A/Influenza B/COVID-19 "ABC" Test has been approved for sale in Mexico by the Mexican Department of Epidemiology (InDRE). This clearance follows a successful independent evaluation of the test's sensitivity and specificity. Following the CE marking, demand has surged for the ABC multiplex diagnostic, particularly as flu season approaches amidst reduced immunity predictions. The company views this approval as validation of its CoPrimer™ platform and a step toward enhancing access to affordable diagnostics.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.52%
Tags
none
-
Rhea-AI Summary

Co-Diagnostics, Inc. (NASDAQ: CODX) will present at the Sidoti Fall Virtual Investor Conference on September 23, 2021, at 3:15 p.m. EDT. The presentation will be led by CEO Dwight Egan, CFO Brian Brown, and Head of Investor Relations Andrew Benson. Investors can access the event through the Co-Diagnostics website. Registration for the presentation and one-on-one meetings is available at www.sidoti.com/events.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.52%
Tags
conferences
Rhea-AI Summary

Co-Diagnostics (Nasdaq: CODX) announced that its joint venture, CoSara Diagnostics, received clearance from India's CDSCO to manufacture and sell Saragene™ dengue and chikungunya RT-PCR tests as in vitro diagnostics. Utilizing Co-Diagnostics' patented CoPrimer™ technology, these tests aim to accurately detect these mosquito-borne viruses, addressing a significant public health issue as the incidence of dengue has dramatically increased globally. CEO Dwight Egan emphasized the importance of accurate diagnosis for effective treatment and highlighted CoSara's prior approvals for various tests in India.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.86%
Tags
none
-
Rhea-AI Summary

Co-Diagnostics, Inc. (Nasdaq-CM: CODX) announced today that CEO Dwight Egan will join a panel discussion titled "How We Can Defeat the Next Pandemic," hosted by Scott Gottlieb, M.D., at the H.C. Wainwright & Co. 2021 Global Investor Conference. This virtual event is scheduled for September 15, 2021, at 12:00 pm ET. Attendees can register for the conference here. Additionally, Mr. Egan and CFO Brian Brown will present a Healthcare & Biotech On-Demand session available starting September 13, 2021, at 7:00 am ET on their website.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.29%
Tags
conferences
-
Rhea-AI Summary

Co-Diagnostics (Nasdaq: CODX) announced that its Logix Smart™ COVID-19 Test Kit was utilized by Italian researchers to detect SARS-CoV-2, including mutated strains, through community surveillance testing of discarded saliva samples. The peer-reviewed results were published in Science of the Total Environment. The study involved testing items like plastic cups and bottles across 20 sites in Northern Italy during the COVID-19 peak in early 2021. CEO Dwight Egan emphasized the importance of this study, highlighting the test's effectiveness in identifying viral presence in environmental samples.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.86%
Tags
none
Rhea-AI Summary

Co-Diagnostics, Inc. (Nasdaq-CM: CODX) will showcase its innovations at the 13th Annual Next Generation Dx Summit from August 24-26, 2021, in Washington, D.C. The summit focuses on critical issues in diagnostics, featuring streams on Point-of-Care Testing (POCT) and Liquid Biopsy. CEO Dwight Egan is scheduled to present on August 25 at 10:30 am ET, discussing a rapid PCR diagnostics platform designed for POCT applications that aim to streamline testing protocols across various environments. More information on the summit can be found at Next Generation Dx.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.76%
Tags
conferences
-
Rhea-AI Summary

Co-Diagnostics, Inc. (NASDAQ: CODX) reported second-quarter financial results with revenue of $27.4 million, a 13.8% increase year-over-year, driven by the Logix Smart™ COVID-19 Test. Gross profit rose 37.6% to $24.9 million, due to improved production costs. However, operating income fell 19.8% to $11.8 million due to rising sales and marketing expenses. Net income was $9.8 million ($0.33 per share), down from $15.0 million ($0.51 per share) a year earlier. Cash reserves increased to $72.4 million. The company expects Q3 revenue between $23.0 million and $25.0 million.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
9.62%
Tags
-
Rhea-AI Summary

Co-Diagnostics, Inc. (Nasdaq: CODX) will release its second quarter 2021 financial results on August 12, 2021, after market close. The company aims to discuss these results in a conference call at 4:30 p.m. EDT on the same day, featuring CEO Dwight Egan and CFO Brian Brown. Co-Diagnostics focuses on molecular diagnostics with a patented technology for developing diagnostic tests based on nucleic acid detection. The results and call are crucial for investors seeking insights into the company's financial performance and future outlook.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.36%
Tags
Rhea-AI Summary

Co-Diagnostics, Inc. (Nasdaq: CODX) announced the award of a new patent for its CoPrimer™ technology from South Korea's Intellectual Property Office. This adds to the company's growing portfolio of intellectual property, enhancing the protection of its molecular diagnostic tests. The CoPrimer technology underpins tests like the Logix Smart™ COVID-19 Test kit, which has sold millions globally since the pandemic's onset. Co-Diagnostics emphasizes the durability of its sales model and the significant demand from repeat customers.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
21.15%
Tags
none

FAQ

What is the current stock price of Co-Diagnostics (CODX)?

The current stock price of Co-Diagnostics (CODX) is $0.73 as of December 20, 2024.

What is the market cap of Co-Diagnostics (CODX)?

The market cap of Co-Diagnostics (CODX) is approximately 23.6M.

What does Co-Diagnostics, Inc. specialize in?

Co-Diagnostics, Inc. specializes in molecular diagnostics with unique, patented technology for faster, more efficient DNA testing for various diseases.

Where is Co-Diagnostics headquartered?

Co-Diagnostics is headquartered in Sandy, Utah, USA.

What diseases can Co-Diagnostics' tests diagnose?

Co-Diagnostics offers tests for diseases such as tuberculosis, Zika, hepatitis B and C, malaria, dengue, and HIV.

What is the Co-Dx PCR platform?

The Co-Dx PCR platform includes at-home and point-of-care diagnostic solutions, designed to detect and analyze nucleic acid molecules (DNA or RNA).

What recent achievements has Co-Diagnostics made?

Co-Diagnostics recently opened new manufacturing facilities in Salt Lake City and India, enhancing production capabilities for its PCR platform and test kits.

What is the CoSara Diagnostics joint venture?

CoSara Diagnostics is a joint venture between Co-Diagnostics and Sarabhai Group in India, focused on manufacturing and selling diagnostic tests in the Indian market.

What are Co-Primers?

Co-Primers are patented oligonucleotides used in Co-Diagnostics' PCR tests to enhance accuracy and performance.

What regulatory clearances has Co-Diagnostics received in India?

The company's joint venture with CoSara has received CDSCO clearance for multiple diagnostic tests, including influenza and tuberculosis.

What is the FDA status of Co-Diagnostics' products?

Co-Diagnostics has submitted an EUA to the FDA for its Co-Dx PCR Pro™ instrument and COVID-19 test, aiming for future at-home and point-of-care use.

Who are the key executives at Co-Diagnostics?

Key executives include Dwight Egan (CEO) and Brian Brown (CFO).

Co-Diagnostics, Inc.

Nasdaq:CODX

CODX Rankings

CODX Stock Data

23.60M
29.79M
6.7%
13.96%
0.72%
Medical Devices
Surgical & Medical Instruments & Apparatus
Link
United States of America
SALT LAKE CITY